|
2013 Conference Publication Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant PatientsTaylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2013). Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. 55th Annual Meeting of the American Society of Hematology, New Orleans, LA United States, 7-10 December 2013. Washington, DC United States: American Society of Hematology. |
|
2012 Conference Publication Intensive chemotherapy for acute myeloid leukemia in elderly patientsJackson, Kathryn A, Kennedy, Glen A, Mollee, Peter and Morris, Kirk (2012). Intensive chemotherapy for acute myeloid leukemia in elderly patients. 54th ASH Annual Meeting, Atlanta, GA, 8-11 December 2012. American Society of Hematology. doi: 10.1182/blood.v120.21.4341.4341 |
|
2012 Conference Publication Clinical comparison of the freelite and n-latex serum free light chain (FLC) assays in the diagnosis and monitoring of AL amyloidosisMapp, Sally, Tate, Jill, Pretorius, Carel and Mollee, Peter (2012). Clinical comparison of the freelite and n-latex serum free light chain (FLC) assays in the diagnosis and monitoring of AL amyloidosis. 54th ASH Annual Meeting, Atlanta, GA, 8-11 December 2012. American Society of Hematology. doi: 10.1182/blood.v120.21.4991.4991 |
|
2012 Conference Publication Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unitJackson, Kathryn A., Mollee, Peter, Morris, Kirk, Jackson, Dwane L., Kruger, Peter, Klein, Kerenaftali and Kennedy, Glen A. (2012). Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. 54th ASH Annual Meeting, Atlanta, GA United States, 8-11 December 2012. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v120.21.3613.3613 |
|
2012 Journal Article Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphomaKeane, C., Nourse, J. P., Crooks, P., Nguyen-Van, D., Mutsando, H., Mollee, P., Lea, R. A. and Gandhi, M. K. (2012). Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Internal Medicine Journal, 42 (10), 1113-1119. doi: 10.1111/j.1445-5994.2011.02587.x |
|
2012 Journal Article CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitroBurgess, Melinda, Cheung, Catherine, Chambers, Lynne, Ravindranath, Karunya, Minhas, Gunjeet, Knop, Louise, Mollee, Peter, McMillan, Nigel A. J. and Gill, Devinder (2012). CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leukemia and Lymphoma, 53 (10), 1988-1998. doi: 10.3109/10428194.2012.672735 |
|
2012 Journal Article Gamma-delta T-cell lymphoma with CNS involvement presenting with proptosis: A case study workup, treatment and prognosisSugnanam, K., Ooi, L., Mollee, P. and Vu, P. (2012). Gamma-delta T-cell lymphoma with CNS involvement presenting with proptosis: A case study workup, treatment and prognosis. Orbit, 31 (5), 364-366. doi: 10.3109/01676830.2012.711411 |
|
2012 Journal Article A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosisMollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, H.Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy, Fan, Helen Mar and Gill, Devinder S. (2012). A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. British Journal of Haematology, 157 (6), 766-769. doi: 10.1111/j.1365-2141.2012.09080.x |
|
2012 Journal Article Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activityLane, Steven, Gill, Devinder, McMillan, Nigel A. J., Saunders, Nicholas, Murphy, Rachel, Spurr, Terrence, Keane, Colm, Fan, Helen Mar and Mollee, Peter (2012). Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leukemia & Lymphoma, 53 (6), 1077-1083. doi: 10.3109/10428194.2011.642302 |
|
2012 Journal Article Continuous lenalidomide treatment for newly diagnosed multiple myelomaPalumbo, Antonio, Hajek, Roman, Delforge, Michel, Kropff, Martin, Petrucci, Maria Teresa, Catalano, John, Gisslinger, Heinz, Wiktor-Jędrzejczak, Wiesław, Zodelava, Mamia, Weisel, Katja, Cascavilla, Nicola, Iosava, Genadi, Cavo, Michele, Kloczko, Janusz, Bladé, Joan, Beksac, Meral, Spicka, Ivan, Plesner, Torben, Radke, Joergen, Langer, Christian, Ben Yehuda, Dina, Corso, Alessandro, Herbein, Lindsay, Yu, Zhinuan, Mei, Jay, Jacques, Christian, Dimopoulos, Meletios A., MM-015 Investigators and Mollee, Peter (2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England Journal of Medicine, 366 (19), 1759-1769. doi: 10.1056/NEJMoa1112704 |
|
2012 Journal Article Recommendations for standardized reporting of protein electrophoresis in Australia and New ZealandTate, Jillian, Caldwell, Grahame, Daly, James, Gillis, David, Jenkins, Margaret, Jovanovich, Sue, Martin, Helen, Steele, Richard, Wienholt, Louise and Mollee, Peter (2012). Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Annals of Clinical Biochemistry, 49 (3), 242-256. doi: 10.1258/acb.2011.011158 |
|
2012 Journal Article WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidationGray, James X., McMillen, Lyle, Mollee, Peter, Paul, Sanjoy, Lane, Steven, Bird, Robert, Gill, Devinder, Saal, Russell and Marlton, Paula (2012). WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leukemia Research, 36 (4), 453-458. doi: 10.1016/j.leukres.2011.09.005 |
|
2012 Journal Article Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian studyMorel-Kopp, Marie-Christine, Tan, Chee Wee, Brighton, Timothy A., McRae, Simon, Baker, Ross, Huyen Tran, Mollee, Peter, Kershaw, Geoffrey, Joseph, Joanne and Ward, Christopher (2012). Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thrombosis and Haemostasis, 107 (3), 575-583. doi: 10.1160/TH11-09-0631 |
|
2012 Journal Article Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trialTrappe, Ralf, Oertel, Stephan, Leblond, Veronique, Mollee, Peter, Sender, Monica, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Horst, Heinz August, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Leithäuser, Malte, Zimmermann, Heiner, Anagnostopoulos, Ioannis, Raphael, Martine, Riess, Hanno, Choquet, Sylvain and for the German PTLD Study Group and the European PTLD Network (2012). Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. The Lancet Oncology, 13 (2), 196-206. doi: 10.1016/S1470-2045(11)70300-X |
|
2012 Journal Article High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal diseaseMutsando, Howard, Fahim, Magid, Gill, Devinder S., Hawley, Carmel M., Johnson, David W., Maher, K. Gandhi, Marlton, Paula V., Mar Fan, Helen G. and Mollee, Peter N. (2012). High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. American Journal of Blood Research, 2 (1), 66-70. |
|
2012 Conference Publication Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unitJackson, Kathryn A., Mollee, Peter, Morris, Kirk, Jackson, Dwane L., Kruger, Peter, Klein, Kerenaftali and Kennedy, Glen A. (2012). Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unit. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V120.21.3613.3613 |
|
2012 Conference Publication Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly PatientsJackson, Kathryn A., Kennedy, Glen A., Mollee, Peter and Morris, Kirk (2012). Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly Patients. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology. |
|
2011 Conference Publication Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6Keane, Colm, Shen, Linda, Han, Erica, Nourse, Jamie P, Lea, Rod, Mollee, Peter, Gill, Devinder S and Gandhi, Maher K (2011). Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.1585.1585 |
|
2011 Conference Publication A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosisMollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S (2011). A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.3973.3973 |
|
2011 Conference Publication ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL)Mollee, Peter, Banh, Raymond H., Cheung, Catherine, Saal, Russell, Chambers, Lynne, Pelly, Tennille and Gill, Devinder S (2011). ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL). 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.4602.4602 |
